This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Kno ETextbooks Provided By Kaplan Give Aspiring Doctors The Flexibility And Access To Study Anytime, Anywhere

Kaplan Publishing, a leading publisher of academic and professional development resources, has partnered with Kno, a leading education software provider, to bring e-books to medical school students and doctors studying for the United States Medical Licensing Examination. The USMLE, divided into Steps 1, 2 and 3, is taken by tens of thousands of aspiring doctors annually as a requirement to practice medicine in the United States.

The titles included for the Kaplan/Kno partnership are MedEssentials, USMLE Step 1 Microbiology/Immunology, USMLE Step 1 Pharmacology, USMLE Step 2 Internal Medicine, and USMLE Step 2 Surgery.

A recent survey of Kaplan students showed that 97% report owning a tablet device, electronic reader or smartphone. In the survey, students noted the value of portability from print to digital and across devices, accessibility and offline access in their e-books. Noted one student, “It’s nice to have all these books on one small device,” while another observed, “Constant access is useful.” The Kno eTextbooks enable students to carry all their reading on a single device, access their textbooks across many platforms and devices, and conduct their reading offline and on-the-go.

Yet despite students’ overwhelming adoption of smartphones and tablet devices, many still prefer to have the option of reading their books in the traditional print format -- with the majority of students surveyed indicating the desire for both options.

“In an age of Wikipedia and Google, where an overwhelming amount of information is readily available, the key is not just in the right information, but in how it’s delivered. Students want choice in how they prepare for important exams like the USMLE,” said Maureen McMahon, president and publisher, Kaplan Publishing. “Students would ideally prefer to move seamlessly between print and digital formats. It’s important that we help students study in the formats that best meet their preferences and fall within their comfort zones.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs